Earlier in May, in a regulatory filing Lupin had said that the US health regulator had completed inspection of the Nagpur facility without making any observations.
New Delhi: Drug firm Lupin on Friday said it has received an establishment inspection report (EIR) from the US health regulator after the successful inspection of its Nagpur facility. [caption id=“attachment_4185415” align=“alignleft” width=“380”]![Representational image. Getty images.]()
Representational image. Getty images.[/caption] The plant was inspected by the United States Food and Drug Administration (USFDA) in May 2018, Lupin said in a filing to BSE. Commenting on the development, Lupin MD Nilesh Gupta said, “The successful completion of the Nagpur facility inspection is a positive development as we continue our journey to meet and exceed international regulatory standards.” Earlier in May, in a regulatory filing Lupin had said that the US health regulator had completed inspection of the Nagpur facility without making any observations. Shares of Lupin were on Friday trading at Rs 903 per scrip on BSE, down 0.07 percent from its previous close.
- Home
- Business
- Lupin gets establishment inspection report from USFDA for its Nagpur facility
 "Lupin gets establishment inspection report from USFDA for its Nagpur facility")
 "US ready to ‘impose costs’ on Russia if war in Ukraine drags on, says Hegseth")
 "US tells Hamas to stop violence against Gaza civilians and disarm 'without delay'")
 "China seizes 60,000 maps mislabelling Taiwan, omitting South China Sea islands")
 "Syria’s Sharaa pledges to honor Russia ties, seeks economic and military support in Kremlin visit")
 "US ready to ‘impose costs’ on Russia if war in Ukraine drags on, says Hegseth")
 "US tells Hamas to stop violence against Gaza civilians and disarm 'without delay'")
 "China seizes 60,000 maps mislabelling Taiwan, omitting South China Sea islands")
 "Syria’s Sharaa pledges to honor Russia ties, seeks economic and military support in Kremlin visit")
